Seneca Biopharma (NASDAQ: SNCA) and Leading Biosciences said on Thursday that they have entered into a definitive merger agreement which will see a wholly-owned subsidiary of Seneca merge with Leading Biosciences in an all-stock transaction.
In a statement, the companies said that the new combined company will focus on advancing Leading’s lead pipeline asset, LB1148, in clinical studies to evaluate its potential.
Upon completion of the deal, the company is expected to operate under the name Palisade Bio inc and trade on the Nasdaq under the ticker symbol PALI.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Seneca shareholders will own approximately 26.2% of the combined company while Leading Biosciences shareholders will own about 73.8% of the combined company on a fully diluted basis.
Shareholders of Seneca will also receive one contingent value right for each share of Seneca common stock as a dividend.
Investment firm Altium Capital has agreed to invest $22.5 million once the merger is completed.
“Following an extensive review of strategic alternatives, we believe that this merger with Leading BioSciences is in the best interest of Seneca’s stockholders, and has the potential to deliver both near- and long-term value to the stockholders,” commented Kenneth C Carter, executive chairman of Seneca.
Seneca’s stock price initially surged 61% following the merger news. It is currently trading 44.26% higher at $1.12 per share ahead of the US opening bell.
